Table 1.
Demographic and biologic characteristics of the sample.
| ART Naïve (N=7, 8%) |
Non-Suppressive ART (N=64, 71%) |
Suppressive ART (N=19, 21%) |
All subjects (N=90) |
p-value | |
|---|---|---|---|---|---|
| Age (years) mean (SD, N) | 42.0 (11.0, 7) | 42.5 (8.0, 64) | 53.2 (10.9, 19) | 44.7 (9.8, 90) | < 0.001 |
| Male | 6/7 (85.7%) | 51/64 (79.7%) | 17/19 (89.5%) | 74/90 (82.2%) | 0.8 |
| Smoking ever | 1/5 (20.0%) | 24/62 (38.7%) | 8/19 (42.1%) | 33/86 (38.4%) | 0.7 |
| Months from last clinical visit to autopsy mean (SD, N) | 1.4 (0.84, 2) | 6.3 (9.8, 36) | 5.0 (7.5, 8) | 5.9 (9.2, 46) | 0.7 |
| Estimated duration of HIV infection (years) (SD, N) | 6.1 (5.9, 4) | 12.7 (5.2, 42) | 13.6 (7.2, 15) | 12.5 (5.9, 61) | 0.07 |
| Diabetes | 0 /6 (0%) | 3/63 (4.8%) | 4/19 (21.1%) | 7/88 (8.0%) | 0.08 |
| Hypertension | 1/6 (16.7%) | 19/63 (30.2%) | 9/19 (47.4%) | 29/88 (33.0%) | 0.3 |
| Hyperlipidemia | 0/6 (0%) | 7/63 (11.1%) | 6/19 (31.6%) | 13/88 (14.8%) | 0.09 |
| Hepatitis C coinfection | 4/7 (57.1%) | 17/63 (27.0%) | 10/19 (52.6%) | 31/89 (34.8%) | 0.05 |
| CNS penetration effectiveness score mean (SD, N) | N/Aa | 7.8 (3.1, 16) | 7.7 (2.2, 6) | 7.8 (2.9, 22) | 0.9 |
| HIVE | 4/7 (57.1%) | 13/64 (20.3%) | 1/19 (5.3%) | 18/90 (20.0%) | 0.02 |
| HAND: Impaired | 2/2 (100%) | 21/36 (58.3%) | 3/8 (37.5%) | 26/46 (56.5%) | 0.3 |
| HIV plasma RNA (log10) mean (SD, N) | 5.02 (0.6, 6) | 4.7 (1.3, 64) | N/Ab | 4.71 (1.28, 70) | 0.8 |
| HIV CSF RNA (log10) mean (SD, N) | 3.3 (0, 1) | 3.6 (1.5, 29) | 2.2 (1.3, 6) | 3.34 (1.5, 36) | 0.12 |
| Frontal cortex HIV RNA (log10) mean (SD, N) | 7.7 (0.3, 2) | 4.9 (1.8, 20) | 3.3 (1.0, 3) | 4.9 (1.9, 25) | 0.03 |
| Frontal cortex HIV p24 (log10) mean (SD, N) | 1.76 (0.93, 5) | 1.05 (0.65, 36) | 0.83 (0.23, 10) | 1.08 (0.66, 51) | 0.03 |
HIVE: HIV encephalitis. HAND: HIV associated neurocognitive disorders.
a
No data available.
b
S-ART group was defined based on undetectable plasma viral load.